Analytica's lead product is the PeriCoach® System - an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles during pregnancy, childbirth and menopause.

PeriCoach® comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal.

This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach® has Australia regulatory clearance in Australia, CE mark and FDA 510(k) clearance. The US market for incontinence pads is $5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence. PeriCoach® is available from the website.

PeriCoach also has TGA clearance for the treatment of Pelvic Organ Prolapse, a condition which affects 1 in 6 women during their lifetimes.

Investment Information

Analytica Limited (ABN 12 006 464 866) is a Brisbane-based public company listed on the Australian Stock Exchange (ASX Code: ALT). For more information, see About Us and ASX Releases.

Corporate Governance

Recent News